Access cutting-edge human immunodeficiency virus type 1 (hiv-1) infection treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Washington Dc location
Preparing your pre-screening questions…
Access human immunodeficiency virus type 1 (hiv-1) infection specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related human immunodeficiency virus type 1 (hiv-1) infection treatment provided free
Check if you qualify for this human immunodeficiency virus type 1 (hiv-1) infection clinical trial in Washington Dc, DC
No-Cost Study Care
Local to Washington Dc
Convenient for DC residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in the body. Standard ART helps people live longer, but people must take up to 3 medicines up to twice a day. Standard ART may also cause other health problems. Researchers want to know if a study ART works as well as a standard ART to treat HIV-1. The study ART combines 2 medicines, islatravir and ulonivirine, and is taken once a week. The goals of this study are to learn: 1) If the study ART works as well as a standard ART to treat HIV-1, and 2) About the safety of the study ART and if people tolerate it compared to a standard ART.
Sponsor: Merck Sharp & Dohme LLC
Yes, this clinical trial (NCT07266831) has an active research site in Washington Dc, DC that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for human immunodeficiency virus type 1 (hiv-1) infection treatment options in Washington Dc, DC, this clinical trial (NCT07266831) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced human immunodeficiency virus type 1 (hiv-1) infection specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all human immunodeficiency virus type 1 (hiv-1) infection clinical trials near you to find additional studies recruiting in your area.
See all multiple myeloma clinical trials recruiting in Washington Dc — not just this study.
Browse Multiple Myeloma Trials in Washington Dc →